Abstract Library

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#4256 Epigenetic prediction of aging and metabolic traits provides insight into tumor biology in multi-focal ileal neuroendocrine tumors

Introduction: Approximately half of small intestinal neuroendocrine tumors (siNETs) are multifocal, and recent investigations into the genetic architecture of these tumors have found that they are not clonal. Due to the low mutational rate and slow growing nature of these small tumors, the ‘timing’ of the development of individual tumors has not been possible.

Conference:

Presenting Author:

Authors: Webster A, Makinen N, Ecker S, Beck S, Nakakura E,

Keywords: DNA methylation, Epigenetics, Multifocal Ileal Neuroendocrine Tumor, Multifocal Small Instestinal NET, Metabolic Traits,

#4253 New insight in the environment immunephenotyping of gastroenteropancreatic neuroendocrine neoplasms: CD 90 expression

Introduction: Neuroendocrine neoplasms (NEN) represent a particular model of host-tumor interaction. CD90 (Thy-1) is a glycoprotein involved in cell–cell/cell–matrix interactions and is associated to stem phenotype and metastatic potential.

Conference:

Presenting Author:

Authors: Verrico M, Botticelli A, Feola T, Di Gioia C, Scagnoli S,

Keywords: cd 90, neuroendocrine neoplasm,

#3789 Comparison of postoperative textbook outcome between pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma – A nationwide retrospective cohort study

Introduction: Pancreatic neuroendocrine tumors (pNET) represent only 6% of pancreatic tumors, compared to 93% for pancreatic ductal adenocarcinoma (PDAC). Textbook outcome (TO) is a composite outcome measure that reflects a hospital’s surgical performance as well as quality of current practice.

Conference:

Presenting Author: Chen J

Authors: Chen J, Augustinus S, Engelsman A, Bonsing B, Groot Koerkamp B,

Keywords: pNET, PDAC, Dutch Pancreatic Cancer Audit, Textbook Outcome, Postoperative results,